The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

Session information

Symposium

[S43] Current Status and Issues of Nucleic Acid Drug Development

Mon. Mar 27, 2023 1:50 PM - 3:50 PM [Room M1] The Alumni Hall "Frate": Hall (1F)

Organizer: Junji Kawakami, Takao Inoue, Satoshi Obika

Nucleic acid drugs allow versatile molecular design that does not depend on the structure or physical properties of the target protein, and their practical application has been rapidly progressing, especially since 2016. Although most of these nucleic acid drugs have been developed overseas, the first domestically produced nucleic acid drugs were approved in Japan and the U.S. in 2020, and many nucleic acid drugs are currently undergoing preclinical and clinical trials. In preparation for the accelerated development of nucleic acid drugs and their subsequent application for approval in Japan, it is an urgent issue for industry, government, and academia to reach a consensus on how the quality control of nucleic acid drugs should be. In this symposium, we will discuss the issues that need to be resolved in the near future with regard to CMC (Chemistry, Manufacturing and Control) of nucleic acid drugs, based on the past efforts in industry, government and academia. In addition, we will introduce our activity in the AMED project for the development of basic drug discovery technologies for the realization of next-generation therapies and diagnostics (development of RNA-targeted drug discovery technologies).

シンポジウム趣旨説明:川上 純司, 井上 貴雄(甲南大FIRST, 国衛研) (1:50 PM - 1:55 PM)

2:30 PM - 2:50 PM

○Mitsuaki Sekiguchi1,8, Naomi Takiguchi2,8, Natsuki Kobayashi3,8, Yuko Kobayashi4,8, Junichi Mizoguchi5,8, Jun Saito6,8, Aya Ishihara7,8 (1. Shionogi & Co.,Ltd., 2. Sumitomo Pharma Co.,Ltd., 3. AstraZeneca K.K., 4. Sanofi K.K., 5. Eisai Co.,Ltd., 6. Kyowa Kirin Co.,Ltd., 7. Janssen Pharmaceutical K.K., 8. JPMA Oligonucleotide Quality Task Force)

×

Authentication

×

Please log in with your participant account.
» Participant Log In